These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

215 related items for PubMed ID: 7484858

  • 1. Electrophysiologic profile and efficacy of intravenous dofetilide (UK-68,798), a new class III antiarrhythmic drug, in patients with sustained monomorphic ventricular tachycardia. Dofetilide Arrhythmia Study Group.
    Bashir Y, Thomsen PE, Kingma JH, Møller M, Wong C, Cobbe SM, Jordaens L, Campbell RW, Rasmussen HS, Camm AJ.
    Am J Cardiol; 1995 Nov 15; 76(14):1040-4. PubMed ID: 7484858
    [Abstract] [Full Text] [Related]

  • 2. A randomized, double-blind, placebo-controlled, dose-ranging study of dofetilide in patients with inducible sustained ventricular tachyarrhythmias.
    Echt DS, Lee JT, Murray KT, Vorperian V, Borganelli SM, Crawford DM, Friedrich T, Roden DM.
    J Cardiovasc Electrophysiol; 1995 Sep 15; 6(9):687-99. PubMed ID: 8556189
    [Abstract] [Full Text] [Related]

  • 3. A multicentre, double-blind randomized crossover comparative study on the efficacy and safety of dofetilide vs sotalol in patients with inducible sustained ventricular tachycardia and ischaemic heart disease.
    Boriani G, Lubinski A, Capucci A, Niederle R, Kornacewicz-Jack Z, Wnuk-Wojnar AM, Borggrefe M, Brachmann J, Biffi M, Butrous GS, Ventricular Arrhythmias Dofetilide Investigators.
    Eur Heart J; 2001 Dec 15; 22(23):2180-91. PubMed ID: 11913480
    [Abstract] [Full Text] [Related]

  • 4. Dofetilide reduces the frequency of ventricular arrhythmias and implantable cardioverter defibrillator therapies.
    Baquero GA, Banchs JE, Depalma S, Young SK, Penny-Peterson ED, Samii SM, Wolbrette DL, Naccarelli GV, Gonzalez MD.
    J Cardiovasc Electrophysiol; 2012 Mar 15; 23(3):296-301. PubMed ID: 21955243
    [Abstract] [Full Text] [Related]

  • 5. Effects of the class III antiarrhythmic drug dofetilide on ventricular monophasic action potential duration and QT interval dispersion in stable angina pectoris.
    Sedgwick ML, Rasmussen HS, Cobbe SM.
    Am J Cardiol; 1992 Dec 01; 70(18):1432-7. PubMed ID: 1442614
    [Abstract] [Full Text] [Related]

  • 6. Dofetilide, a novel class III antiarrhythmic agent.
    Rasmussen HS, Allen MJ, Blackburn KJ, Butrous GS, Dalrymple HW.
    J Cardiovasc Pharmacol; 1992 Dec 01; 20 Suppl 2():S96-105. PubMed ID: 1279316
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and safety of intravenously administered dofetilide in acute termination of atrial fibrillation and flutter: a multicenter, randomized, double-blind, placebo-controlled trial. Danish Dofetilide in Atrial Fibrillation and Flutter Study Group.
    Nørgaard BL, Wachtell K, Christensen PD, Madsen B, Johansen JB, Christiansen EH, Graff O, Simonsen EH.
    Am Heart J; 1999 Jun 01; 137(6):1062-9. PubMed ID: 10347332
    [Abstract] [Full Text] [Related]

  • 8. Effects of dofetilide, a class III antiarrhythmic drug, on various ventricular arrhythmias in dogs.
    Chen J, Xue Y, Eto K, Ni C, Hashimoto K.
    J Cardiovasc Pharmacol; 1996 Oct 01; 28(4):576-84. PubMed ID: 8891885
    [Abstract] [Full Text] [Related]

  • 9. Intravenous dofetilide, a class III antiarrhythmic agent, for the termination of sustained atrial fibrillation or flutter. Intravenous Dofetilide Investigators.
    Falk RH, Pollak A, Singh SN, Friedrich T.
    J Am Coll Cardiol; 1997 Feb 01; 29(2):385-90. PubMed ID: 9014993
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and safety of dofetilide, a new class III antiarrhythmic agent, in acute termination of atrial fibrillation or flutter after coronary artery bypass surgery. Dofetilide Post-CABG Study Group.
    Frost L, Mortensen PE, Tingleff J, Platou ES, Christiansen EH, Christiansen N.
    Int J Cardiol; 1997 Jan 31; 58(2):135-40. PubMed ID: 9049678
    [Abstract] [Full Text] [Related]

  • 11. Dofetilide: a new class III antiarrhythmic agent.
    Roukoz H, Saliba W.
    Expert Rev Cardiovasc Ther; 2007 Jan 31; 5(1):9-19. PubMed ID: 17187453
    [Abstract] [Full Text] [Related]

  • 12. Phase IV trial evaluating the effectiveness and safety of dofetilide.
    Guanzon AV, Crouch MA.
    Ann Pharmacother; 2004 Jan 31; 38(7-8):1142-7. PubMed ID: 15161945
    [Abstract] [Full Text] [Related]

  • 13. Electrophysiologic and antiarrhythmic effects of the new class III antiarrhythmic drug KCB-328 in experimental canine atrial flutter.
    Rahme MM, Ungab GA, Wadhwa M, Al-Kandari F, Yao B, Gupta A, Lee K, Kim HY, Feld GK.
    J Cardiovasc Pharmacol Ther; 2001 Jul 31; 6(3):297-306. PubMed ID: 11584336
    [Abstract] [Full Text] [Related]

  • 14. Prediction of antiarrhythmic efficacy of class I and III agents in patients with ventricular tachycardia by signal-averaged ECG analysis.
    Kulakowski P, Bashir Y, Heald S, Paul V, Anderson MH, Gibson S, Malik M, Camm AJ.
    Pacing Clin Electrophysiol; 1992 Nov 31; 15(11 Pt 2):2116-21. PubMed ID: 1279610
    [Abstract] [Full Text] [Related]

  • 15. Combined potassium and calcium channel blocking activities as a basis for antiarrhythmic efficacy with low proarrhythmic risk: experimental profile of BRL-32872.
    Bril A, Gout B, Bonhomme M, Landais L, Faivre JF, Linee P, Poyser RH, Ruffolo RR.
    J Pharmacol Exp Ther; 1996 Feb 31; 276(2):637-46. PubMed ID: 8632331
    [Abstract] [Full Text] [Related]

  • 16. Dofetilide: a review of its use in atrial fibrillation and atrial flutter.
    McClellan KJ, Markham A.
    Drugs; 1999 Dec 31; 58(6):1043-59. PubMed ID: 10651390
    [Abstract] [Full Text] [Related]

  • 17. Dofetilide: a new pure class III antiarrhythmic agent.
    Falk RH, Decara JM.
    Am Heart J; 2000 Nov 31; 140(5):697-706. PubMed ID: 11054613
    [Abstract] [Full Text] [Related]

  • 18. Effects of intravenous dofetilide on induction of atrioventricular re-entrant tachycardia.
    Cobbe SM, Campbell RW, Camm AJ, Nathan AW, Rowland E, Bloch-Thomsen PE, Møller M, Jordaens L.
    Heart; 2001 Nov 31; 86(5):522-6. PubMed ID: 11602544
    [Abstract] [Full Text] [Related]

  • 19. Effects of dofetilide on electrical dispersion and arrhythmias in post-infarcted anesthetized dogs.
    D'Alonzo AJ, Sewter JC, Darbenzio RB, Hess TA.
    Basic Res Cardiol; 1995 Nov 31; 90(5):424-34. PubMed ID: 8585865
    [Abstract] [Full Text] [Related]

  • 20. Pharmacodynamics and pharmacokinetics of the class III antiarrhythmic agent dofetilide (UK-68,798) in humans.
    Tham TC, MacLennan BA, Burke MT, Harron DW.
    J Cardiovasc Pharmacol; 1993 Mar 31; 21(3):507-12. PubMed ID: 7681516
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.